InsiderDB

Lobbying disclosures · Lobbying report

PFE: second_quarter 2026 lobbying report

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues

Follow PFE
Became public
Jul 9, 2026, 10:30 AM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 4:19 PM EST

Why this is connected

Exact legal-name match: PFIZER INC (https://www.sec.gov/Archives/edgar/data/78003/).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/455f86ab-6b7f-44b3-857c-969e1efc374a/","filing_uuid":"455f86ab-6b7f-44b3-857c-969e1efc374a","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/455f86ab-6b7f-44b3-857c-969e1efc374a/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-09T10:30:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"611 2nd Street, NE","registrant_address_2":"Suite 1","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":401105121,"url":"https://lda.gov/api/v1/registrants/401105121/","house_registrant_id":44305,"name":"MARSHALL & POPP, LLC","description":"​Government affairs and consulting firm.","address_1":"611 2nd Street, NE","address_2":"Suite 1","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-321-1811","dt_updated":"2026-07-13T16:40:37.032909-04:00"},"client":{"id":210229,"url":"https://lda.gov/api/v1/clients/210229/","client_id":214,"name":"PFIZER, INC.","general_description":"Biopharmaceutical manufacturing.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-05-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":"Policy Director, Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles","new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to tariff and trade policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

+0.31% PFE

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in PFE

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.